Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.74 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7648886 | 0.95 | PPARG (0.81) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6301559 | 0.94 | PPARG (0.80) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6301174 | 0.93 | PPARG (0.79) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6301603 | 0.93 | PPARG (0.79) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6135000 | 0.93 | PPARG (0.79) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6301248 | 0.92 | PPARG (0.77) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7649110 | 0.91 | PPARG (0.80) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6303365 | 0.89 | PPARG (0.81) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7650777 | 0.88 | PPARG (0.91) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6470764 | 0.87 | PPARG (0.74) | PPARGHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6420409-B1 | GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | claimed |
| EP-1020452-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | claimed |
| CN-1135224-C | Benzimidazole derivatives | ����ҩƷ��ҵ��ʽ���� | 2004-01-21 | — | — | CN | disclosed |
| US-6420409-B1 | GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| CN-1268123-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-09-27 | — | — | CN | disclosed |
| EP-1020452-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |